Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Vanda Pharmaceuticals Inc VNDA

Healthcare Biotechnology
Vanda Pharmaceuticals Inc. is a biopharmaceutical company, which is focused on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The Company’s commercial portfolio is comprised of three products: HETLIOZ for the treatment of non-24-hour sleep-wake disorder (Non-24) and for the treatment of nighttime sleep disturbances in... see more

Recent & Breaking News (NDAQ:VNDA)

Vanda Gets FDA Approval For Fanapt Marketing Exclusivity

Benzinga.com  June 15, 2016

FDA Grants Fanapt® Three Years of Marketing Exclusivity for Labeling Changes Relating to Maintenance Treatment of Schizophrenia

PR Newswire June 15, 2016

Vanda Pharmaceuticals to Present at the Jefferies 2016 Healthcare Conference

PR Newswire June 3, 2016

Vanda Announces FDA Approval of the Fanapt® Supplemental New Drug Application for Maintenance Treatment of Schizophrenia in Adults

PR Newswire May 26, 2016

Vanda Pharmaceuticals Reports First Quarter 2016 Financial Results

PR Newswire May 4, 2016

Vanda Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 4, 2016

PR Newswire April 14, 2016

Biotech Sector Report Analyst Coverage Focusing on Upcoming FDA Decisions

Accesswire March 28, 2016

Vanda Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results

PR Newswire February 10, 2016

Vanda Pharmaceuticals to Participate in the Canaccord Genuity Rare Disease, Biopharma One-on-One Day

PR Newswire February 1, 2016

Vanda Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on February 10, 2016

PR Newswire January 22, 2016

Vanda Pharmaceuticals Reports Preliminary Fourth Quarter and Full Year 2015 Results and 2016 Financial Guidance

PR Newswire January 11, 2016

Innovation Sparks Advancement of New Treatments for Atopic Dermatitis

Accesswire January 7, 2016

European Medicines Agency Accepts Fanaptum® (iloperidone) Marketing Authorization Application for the Treatment of Schizophrenia in Adults

PR Newswire December 22, 2015

Equities Lead Investor Sentiment - Free Research on NOW, Vanda Pharmaceuticals, Inovalon Holdings and Bonanza Creek Energy

Accesswire December 21, 2015

Kenneth Bate Joins the Board of Directors of Vanda Pharmaceuticals

PR Newswire December 18, 2015

Vanda Pharmaceuticals appoints Gian Piero Reverberi as Acting Chief Commercial Officer

PR Newswire December 17, 2015

Market Influences That Drive Equities Forward - Research on Rexnord, NOW, Vanda Pharmaceuticals and Inovalon Holdings

Accesswire December 10, 2015

Where Opportunity is Found - Research on Varonis Systems, Glu Mobile, Cytokinetics and Vanda Pharmaceuticals

Accesswire November 25, 2015

The Price Data Tells the Story - Research on Varonis, Glu Mobile, Cytokinetics and Vanda Pharmaceuticals

Accesswire November 17, 2015

Vanda Pharmaceuticals Announces Participation at Upcoming Investor Conferences

PR Newswire November 12, 2015